|
1
|
Harris MA, Yang H, Low BE, Mukherjee J,
Guha A, Bronson RT, Shultz LD, Israel MA and Yun K: Cancer stem
cells are enriched in the side population cells in a mouse model of
glioma. Cancer Res. 68:10051–10059. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haraguchi N, Inoue H, Tanaka F, Mimori K,
Utsunomiya T, Sasaki A and Mori M: Cancer stem cells in human
gastrointestinal cancers. Hum Cell. 19:24–29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kondo T, Setoguchi T and Taga T:
Persistence of a small subpopulation of cancer stem-like cells in
the C6 glioma cell line. Proc Natl Acad Sci USA. 101:781–786. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prince ME, Sivanandan R, Kaczorowski A,
Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles
LE: Identification of a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma. Proc Natl
Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wicha MS, Liu S and Dontu G: Cancer stem
cells: An old idea-a paradigm shift. Cancer Res. 66:1883–1890;
discussion 1895–1896. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sharifi N, Gulley JL and Dahut WL:
Androgen deprivation therapy for prostate cancer. JAMA.
294:238–244. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sharifi N, Hurt EM and Farrar WL: Androgen
receptor expression in prostate cancer stem cells: Is there a
conundrum? Cancer Chemother Pharmacol. 62:921–923. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hurt EM, Kawasaki BT, Klarmann GJ, Thomas
SB and Farrar WL: CD44+ CD24(−) prostate cells are early cancer
progenitor/stem cells that provide a model for patients with poor
prognosis. Br J Cancer. 98:756–765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duhagon MA, Hurt EM, Sotelo-Silveira JR,
Zhang X and Farrar WL: Genomic profiling of tumor initiating
prostatospheres. BMC Genomics. 11:3242010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Klarmann GJ, Hurt EM, Mathews LA, Zhang X,
Duhagon MA, Mistree T, Thomas SB and Farrar WL: Invasive prostate
cancer cells are tumor initiating cells that have a stem cell-like
genomic signature. Clin Exp Metastasis. 26:433–446. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu S, Li N and Lv J: Investigation of the
use of Chinese medicine in patients with malignant conditions.
Zhong Guo Zhong Yi Yao Xin Xi Za Zhi. 17:1–3. 2010.(In
Chinese).
|
|
17
|
Smith M and Boon HS: Counseling cancer
patients about herbal medicine. Patient Educ Couns. 38:109–120.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin HS and Zhang Y: Evidence-based medical
study of TCM on no small cell lung cancer. Shi Jie Ke Xue Ji
Shu-Zhong Yi Yao Xian Dai Hua Za Zhi. 10:121–125. 2008.(In
Chinese).
|
|
19
|
Yang YF, Ge JZ, Wu Y, Xu Y, Liang BY, Luo
L, Wu XW, Liu DQ, Zhang X, Song FX and Geng ZY: Cohort study on the
effect of a combined treatment of traditional Chinese medicine and
western medicine on the relapse and metastasis of 222 patients with
stage I and III colorectal cancer after radical operation. Chin J
Integr Med. 14:251–256. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao L, Yan S and Jiang T: Inhibitory
effect of liuwei dihuang decoction on induced mutation and
spontaneous tumor. Zhong Xi Yi Jie He Za Zhi. 10:433–435. 1990.(In
Chinese). PubMed/NCBI
|
|
21
|
Liang JT, Yan CY, Wang SF, Wu G and Wen
PG: Experimental cancer research Liuwei Dihuang Wan prevention.
Zhong Yi Za Zhi. 6:71–74. 1983.(In Chinese).
|
|
22
|
He XX, Yan C and Endi W: The analysis of
the cyto-diagnosis results of liuweidihuangwan treating esophagel
precancerous disease and gastric precancerous disease. Hebei Yiyao.
9:4–6. 1998.(In Chinese).
|
|
23
|
Zhang Y and Lin HS: Tumor stem cells may
be the final target of traditional Chinese medicine in preventing
cancer recurrence and metastasis. Zhongguo Zhong Xi Yi Jie He Za
Zhi. 29:461–463. 2009.(In Chinese). PubMed/NCBI
|
|
24
|
Guzman ML, Rossi RM, Karnischky L, Li X,
Peterson DR, Howard DS and Jordan CT: The sesquiterpene lactone
parthenolide induces apoptosis of human acute myelogenous leukemia
stem and progenitor cells. Blood. 105:4163–4169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawasaki BT, Hurt EM, Kalathur M, Duhagon
MA, Milner JA, Kim YS and Farrar WL: Effects of the sesquiterpene
lactone parthenolide on prostate tumor-initiating cells: An
integrated molecular profiling approach. Prostate. 69:827–837.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Zhang T, Korkaya H, Liu S, Lee HF,
Newman B, Yu Y, Clouthier SG, Schwartz SJ, Wicha MS and Sun D:
Sulforaphane, a dietary component of broccoli/broccoli sprouts,
inhibits breast cancer stem cells. Clin Cancer Res. 16:2580–2590.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Volate SR, Kawasaki BT, Hurt EM, Milner
JA, Kim YS, White J and Farrar WL: Gossypol induces apoptosis by
activating p53 in prostate cancer cells and prostate
tumor-initiating cells. Mol Cancer Ther. 9:461–470. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stickel F, Brinkhaus B, Krähmer N, Seitz
HK, Hahn EG and Schuppan D: Antifibrotic properties of botanicals
in chronic liver disease. Hepatogastroenterology. 49:1102–1108.
2002.PubMed/NCBI
|
|
29
|
Zhou L, Chow M and Zuo Z: Improved quality
control method for Danshen products-consideration of both
hydrophilic and lipophilic active components. J Pharm Biomed Anal.
41:744–750. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peng ZS, Rao RS, Ni YW, Tan YS and Gong
ZF: Hepatic artery blood medicine treatment of advanced liver
cancer efficacy. Zhong Xi Yi Jie He Za Zhi. 13:330–332. 1993.(In
Chinese).
|
|
31
|
Zhang X, Liu ZH, Liu Y, Zhang ZH, Wan CC,
Xia YJ, Jiang Z, Jin YJ, Wang YW and Lu GQ: The effect of compound
prescription salvia miltiorrhiza inoculation fluid (CPSMIF) in the
treatment of leukemia patients combined with acute tumor
dissolution synthesis (ATDS). Xian Dai Zhong Liu Yi Xue Za Zhi.
18:1204–1206. 2010.(In Chinese).
|
|
32
|
Kim SY, Moon TC, Chang HW, Son KH, Kang SS
and Kim HP: Effects of tanshinone I isolated from salvia
miltiorrhiza bunge on arachidonic acid metabolism and in vivo
inflammatory responses. Phytother Res. 16:616–620. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ng TB, Liu F and Wang ZT: Antioxidative
activity of natural products from plants. Life Sci. 66:709–723.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sung HJ, Choi SM, Yoon Y and An KS:
Tanshinone IIA, an ingredient of salvia miltiorrhiza BUNGE, induces
apoptosis in human leukemia cell lines through the activation of
caspase-3. Exp Mol Med. 31:174–178. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gong Y, Li Y, Lu Y, Li L, Abdolmaleky H,
Blackburn GL and Zhou JR: Bioactive tanshinones in salvia
miltiorrhiza inhibit the growth of prostate cancer cells in vitro
and in mice. Int J Cancer. 129:1042–1052. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park IJ, Kim MJ, Park OJ, Park MG, Choe W,
Kang I, Kim SS and Ha J: Cryptotanshinone sensitizes DU145 prostate
cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and
MAPK regulation. Cancer Lett. 298:88–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ,
Han DC and Kwon BM: Cryptotanshinone inhibits constitutive signal
transducer and activator of transcription 3 function through
blocking the dimerization in DU145 prostate cancer cells. Cancer
Res. 69:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hur JM, Shim JS, Jung HJ and Kwon HJ:
Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in
vitro. Exp Mol Med. 37:133–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou Z, Zheng J and Xu W: Study on the
effect of ofloxacin and tanshinone IIA on human leukocyte
chemotactic migration in vitro. Zhongguo Yi Xue Ke Xue Yuan Xue
Bao. 19:232–235. 1997.(In Chinese). PubMed/NCBI
|
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tay Y, Zhang J, Thomson AM, Lim B and
Rigoutsos I: MicroRNAs to Nanog, OCT4 and SOX2 coding regions
modulate embryonic stem cell differentiation. Nature.
455:1124–1128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Funayama N, Fagotto F, McCrea P and
Gumbiner BM: Embryonic axis induction by the armadillo repeat
domain of beta-catenin: Evidence for intracellular signaling. J
Cell Biol. 128:959–968. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li L and Neaves WB: Normal stem cells and
cancer stem cells: The niche matters. Cancer Res. 66:4553–4557.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Avigdor A, Goichberg P, Shivtiel S, Dar A,
Peled A, Samira S, Kollet O, Hershkoviz R, Alon R, Hardan I, et al:
CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of
human CD34+ stem/progenitor cells to bone marrow. Blood.
103:2981–2989. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ehtesham M, Mapara KY, Stevenson CB and
Thompson RC: CXCR4 mediates the proliferation of glioblastoma
progenitor cells. Cancer Lett. 274:305–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem cells in
glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Salmaggi A, Boiardi A, Gelati M, Russo A,
Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, Parati EA, La
Porta C, et al: Glioblastoma-derived tumorospheres identify a
population of tumor stem-like cells with angiogenic potential and
enhanced multidrug resistance phenotype. Glia. 54:850–860. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Soeda A, Park M, Lee D, Mintz A,
Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T,
Kassam AB, et al: Hypoxia promotes expansion of the CD133-positive
glioma stem cells through activation of HIF-1alpha. Oncogene.
28:3949–3959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kashyap V, Rezende NC, Scotland KB,
Shaffer SM, Persson JL, Gudas LJ and Mongan NP: Regulation of stem
cell pluripotency and differentiation involves a mutual regulatory
circuit of the NANOG, OCT4 and COX2 pluripotency transcription
factors with polycomb repressive complexes and stem cell microRNAS.
Stem Cells Dev. 18:1093–1108. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Niwa H, Miyazaki J and Smith AG:
Quantitative expression of Oct-3/4 defines differentiation,
dedifferentiation or self-renewal of ES cells. Nat Genet.
24:372–376. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chew JL, Loh YH, Zhang W, Chen X, Tam WL,
Yeap LS, Li P, Ang YS, Lim B, Robson P and Ng HH: Reciprocal
transcriptional regulation of Pou5f1 and SOX2 via the OCT4/SOX2
complex in embryonic stem cells. Mol Cell Biol. 25:6031–6046. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B,
Ng HH and Robson P: Transcriptional regulation of nanog by OCT4 and
SOX2. J Biol Chem. 280:24731–24737. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu
DT, Chen DT and Ying SY: Mir-302 reprograms human skin cancer cells
into a pluripotent ES-cell-like state. RNA. 14:2115–2124. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wilson KD, Venkatasubrahmanyam S, Jia F,
Sun N, Butte AJ and Wu JC: MicroRNA profiling of human-induced
pluripotent stem cells. Stem Cells Dev. 18:749–758. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-MicroRNAS with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A MicroRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Oka Y, Nakajima K, Nagao K, Miura K, Ishii
N and Kobayashi H: 293FT cells transduced with four transcription
factors (OCT4, SOX2, NANOG and LIN28) generate aberrant ES-like
cells. J Stem Cells Regen Med. 6:149–156. 2010.PubMed/NCBI
|
|
58
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW:
Coexpression of OCT4 and nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Field M, Alvarez A, Bushnev S and Sugaya
K: Embryonic stem cell markers distinguishing cancer stem cells
from normal human neuronal stem cell populations in malignant
glioma patients. Clin Neurosurg. 57:151–159. 2010.PubMed/NCBI
|
|
60
|
Kléber M and Sommer L: Wnt signaling and
the regulation of stem cell function. Curr Opin Cell Biol.
16:681–687. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Weidt C, Niggemann B, Kasenda B, Drell TL,
Zänker KS and Dittmar T: Stem cell migration: A quintessential
stepping stone to successful therapy. Curr Stem Cell Res Ther.
2:89–103. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cronin PA, Wang JH and Redmond HP: Hypoxia
increases the metastatic ability of breast cancer cells via
upregulation of CXCR4. BMC Cancer. 10:2252010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Onoue T, Uchida D, Begum NM, Tomizuka Y,
Yoshida H and Sato M: Epithelial-mesenchymal transition induced by
the stromal cell-derived factor-1/CXCR4 system in oral squamous
cell carcinoma cells. Int J Oncol. 29:1133–1138. 2006.PubMed/NCBI
|
